COVID-19 studies for: C19 studies:  HC QHC Q Vitamin DVitamin D IvermectinIVM LY-CoVLY REGN-COV2REGN RemdesivirRMD

Source   Share   Tweet
See all 143 studies
9/24
Safety
Early, Late
Gasperetti et al., EP Europace, doi:10.1093/europace/euaa216 (Peer Reviewed) (not included in the study count)
Arrhythmic safety of hydroxych loroquine in COVID-19 patients from different clinical settings
Safety study of 649 patients finding that HC Q administration is safe for short-term treatment for patients with COVID-19 infection regardless of the clinical setting of delivery, causing only modest QTc prolongation and no directly attributable arrhythmic deaths.
Arrhythmic safety data from a large cohort of patients treated with HC Q alone or in combination with other QT-prolonging drugs.
Source   Share   Tweet
See all 143 studies
Please send us corrections, updates, or comments.
Submit